Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.34 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.34 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonidine SCHEMBL1369983 | 1.00 | MAPT (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL3974275 | 0.98 | ADRA2A (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL1172959 | 0.98 | ADRA2A (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL10972183 | 0.98 | ADRA2A (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL22127030 | 0.98 | MAPT (0.35) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL40751 | 0.98 | ADRA2A (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL9838987 | 0.98 | MAPT (0.35) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL22127029 | 0.96 | MAPT (0.34) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL1369066 | 0.96 | MAPT (0.34) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL27404261 | 0.94 | MAPT (0.37) | MAPTHSP90AA1ADRA2AADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 54678 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121731255-B | Sustained and controlled release transdermal patch and preparation process thereof | 国药瑞福莱药业有限公司 | 2026-05-22 | — | — | CN | claimed |
| EP-3934622-B1 | DELAYED RELEASE METHYLPHENIDATE COMPOSITIONS | AMNEAL COMPLEX PRODUCTS RES LLC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260115354-A1 | HYDROLYZED COLLAGEN COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS OF MAKING AND USING THE SAME | ROCHAL TECHNOLOGIES, LLC (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260115163-A1 | NOVEL TREATMENTS | 3Z EHF (IS) | 2026-04-30 | — | — | US | claimed |
| US-20260115353-A1 | HYDROLYZED COLLAGEN COMPOSITIONS WITH ANTIBIOTICS AND METHODS OF USING THE SAME | ROCHAL TECHNOLOGIES, LLC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-0043659-A1 | Clonidine derivatives useful in the treatment of diarrhoea | BEECHAM GROUP PLC (GB) | 1982-01-13 | — | — | EP | claimed |
| US-4292303-A | Polymeric diffusion matrix containing clonidine | KEY PHARMACEUTICALS, INC. (US) | 1981-09-29 | — | — | US | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | claimed |
| US-4201211-A | Therapeutic system for administering clonidine transdermally | ALZA CORPORATION (US) | 1980-05-06 | — | — | US | claimed |
| US-4122190-A | Treating acromegaly | SANDOZ LTD. (CH) | 1978-10-24 | — | — | US | claimed |
| US-4094964-A | IMMUNOASSAY, HAPTEN, ANTIGEN | HOFFMANN-LA ROCHE INC. (US) | 1978-06-13 | — | — | US | claimed |
| US-4086354-A | TRIMETHAPHAN CAMSYLATE OR CLONIDINE WITH A HYDRAZINO PHENYL SUBSTITUTED PROPIONIC ACID DECARBOXYLASE INHIBITOR | MERCK & CO., INC. (US) | 1978-04-25 | — | — | US | claimed |